nach oben

Current Hematologic Malignancy Reports

Erschienen in:

27.01.2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Central Nervous System Involvement in Peripheral T Cell Lymphoma

verfasst von: Dai Chihara, Yasuhiro Oki

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease.

Recent Findings

Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2–6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement > 1 has been consistently found to be a risk factor for CNS relapse.

Summary

Currently, there is no consensus about indications for CNS prophylactic treatment. A high-dose systemic methotrexate-based regimen is the most commonly used treatment, with or without consolidation with high-dose chemotherapy with autologous stem cell transplantation for both primary and secondary CNS involvement. This approach, however, is generally toxic for older patients. New therapeutic approaches against PTCL are therefore needed.

Menon MP, Nicolae A, Meeker H, Raffeld M, Xi L, Jegalian AG, et al. Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol. 2015;39(12):1719–29. https://doi.org/10.1097/PAS.0000000000000503.CrossRefPubMedPubMedCentral

Ferreri AJ, Blay JY, Reni M, Pasini F, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72. https://doi.org/10.1200/JCO.2003.09.139.CrossRefPubMed

Chihara D, Fowler N, Oki Y, Fanale M, et al. Difference in survival outcome of primary central nervous system lymphoma by histologic types. Blood. 2017:Abstract 4137.

Choi JS, Nam DH, Ko YH, Seo JW, Choi YL, Suh YL, et al. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas. Am J Surg Pathol. 2003;27(7):919–28. https://doi.org/10.1097/00000478-200307000-00007.CrossRefPubMed

Hayakawa T, Takakura K, Abe H, Yoshimoto T, et al. Primary central nervous system lymphoma in Japan—a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neuro-Oncol. 1994;19(3):197–215.CrossRef

Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–24. https://doi.org/10.1111/bjh.14073.CrossRefPubMedPubMedCentral

Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, et al. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244–8. https://doi.org/10.1038/leu.2014.200.CrossRefPubMed

Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460–72. https://doi.org/10.1182/blood-2014-03-559542.CrossRefPubMedPubMedCentral

Shenkier TN, Blay JY, O'Neill BP, Poortmans P, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233–9. https://doi.org/10.1200/JCO.2005.07.109.CrossRefPubMed

10.

•• Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–6. https://doi.org/10.1200/JCO.2012.44.7524. First large study analyzed the survival outcome of relapsed/refractory peripheral T-cell lymphoma.

11.

Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, et al. Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol. 2016;55(5):561–6. https://doi.org/10.3109/0284186X.2015.1118656.CrossRefPubMedPubMedCentral

12.

Chihara D, Fanale MA, Miranda RN, Noorani M, et al. The risk of central nervous system (CNS) relapses in patients with peripheral T-cell lymphoma. Blood. 2016;128(22):4153.

13.

•• Ellin F, Landstrom J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126(1):36–41. https://doi.org/10.1182/blood-2014-12-616961. Large study using population-based data analyzing the risk factor for central nervous system relapse in peripheral T-cell lymphoma.

14.

Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1636–43. https://doi.org/10.1093/annonc/mdq645.CrossRefPubMedPubMedCentral

15.

Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115(26):5427. https://doi.org/10.1182/blood-2010-02-266890.CrossRefPubMed

16.

Network NCC. T-cell lymphomas 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

17.

Teshima T, Akashi K, Shibuya T, Taniguchi S, Okamura T, Harada M, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer. 1990;65(2):327–32. https://doi.org/10.1002/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W.CrossRefPubMed

18.

Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–93. https://doi.org/10.1182/blood-2013-10-530659.CrossRefPubMed

19.

Cheah CY, Seymour JF. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep. 2015;17(6):25.CrossRefPubMed

20.

Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5):1267–73. https://doi.org/10.1093/annonc/mdr440.CrossRefPubMed

21.

Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944–51. https://doi.org/10.1002/cncr.26588.CrossRefPubMed

22.

Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012;159(1):39–49. https://doi.org/10.1111/j.1365-2141.2012.09247.x.CrossRefPubMed

23.

Bernstein SH, Unger JM, Leblanc M, Friedberg J, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114–9. https://doi.org/10.1200/JCO.2008.16.8021.CrossRefPubMedPubMedCentral

24.

Arkenau HT, Chong G, Cunningham D, Watkins D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541–5. https://doi.org/10.1093/annonc/mdl434.CrossRefPubMed

25.

Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072–9. https://doi.org/10.1038/bjc.2014.405.CrossRefPubMedPubMedCentral

26.

Network NCC. Central Nervous System Cancers 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

27.

Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–8. https://doi.org/10.1200/JCO.2017.72.7602.CrossRefPubMed

28.

Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17. https://doi.org/10.1016/0360-3016(92)90538-S.CrossRefPubMed

29.

Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21(24):4483–8. https://doi.org/10.1200/JCO.2003.03.108.CrossRefPubMed

30.

DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643–8. https://doi.org/10.1200/JCO.2002.11.013.CrossRefPubMed

31.

Ferreri AJ, Reni M, Dell’Oro S, Ciceri F, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology. 2001;60(2):134–40. https://doi.org/10.1159/000055310.CrossRefPubMed

32.

O’Brien P, Roos D, Pratt G, Liew K, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18(3):519–26. https://doi.org/10.1200/JCO.2000.18.3.519.CrossRefPubMed

33.

DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–43. https://doi.org/10.1200/JCO.1992.10.4.635.CrossRefPubMed

34.

Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570–4. https://doi.org/10.1200/JCO.2006.06.6910.CrossRefPubMed

35.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47. https://doi.org/10.1016/S1470-2045(10)70229-1.CrossRefPubMed

36.

Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. https://doi.org/10.1182/blood-2014-10-604561.CrossRefPubMedPubMedCentral

37.

Morris PG, Correa DD, Yahalom J, Raizer JJ, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9. https://doi.org/10.1200/JCO.2013.50.4910.CrossRefPubMedPubMedCentral

38.

Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38(6):417–20. https://doi.org/10.1038/sj.bmt.1705452.CrossRefPubMed

39.

Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151–6. https://doi.org/10.1200/JCO.2003.05.024.CrossRefPubMed

40.

Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996;14(2):556–64. https://doi.org/10.1200/JCO.1996.14.2.556.CrossRefPubMed

41.

Schmitz N, Wu HS. Advances In the treatment of secondary CNS lymphoma. J Clin Oncol. 2015;33(33):3851–3. https://doi.org/10.1200/JCO.2015.63.1143.CrossRefPubMed

42.

Korfel A, Elter T, Thiel E, Hanel M, Mohle R, Schroers R, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–70. https://doi.org/10.3324/haematol.2012.077917.CrossRefPubMedPubMedCentral

43.

Ferreri AJ, Donadoni G, Cabras MG, Patti C, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–10. https://doi.org/10.1200/JCO.2015.61.1236.CrossRefPubMed

44.

Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–63. https://doi.org/10.1200/JCO.2015.64.9897.CrossRefPubMed

45.

Grommes C, Pastore A, Gavrilovic I, Kaley T, et al. Single-agent ibrutinib in recurrent/refractory central nervous system lymphoma. Blood. 2016;128(22):783.

46.

Ghesquieres H, Houillier C, Chinot O, Choquet S, et al. Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC Network. Blood. 2016;128(22):785.

47.

Choquet S, Houillier C, Bijou F, Houot R, et al. Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC Network. Blood. 2016;128(22):784.

Titel: Central Nervous System Involvement in Peripheral T Cell Lymphoma
verfasst von: Dai Chihara
Yasuhiro Oki
Publikationsdatum: 27.01.2018
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 1/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0431-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Central Nervous System Involvement in Peripheral T Cell Lymphoma

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

NK/T Cell Lymphoma: Updates in Therapy

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

Twitter Use in the Hematopoietic Cell Transplantation Community

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie